C Hyon1, L Mansour-Hendili1, S Chantot-Bastaraud1, B Donadille1, V Kerlan1, C Dodé1, S Jonard1, B Delemer1, A Gompel1, Y Reznik1, P Touraine1, J P Siffroi1, S Christin-Maitre1. 1. Département de Génétique Médicale (C.H., L.M.H., S.C.B., J.P.S.), Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Universitaire de l'Est Parisien-Hôpital Armand Trousseau, 75012, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM), UMRS 933, Physiopathologie des Maladies Génétiques d'Expression Pédiatrique (C.H., J.P.S., S.C.M.), Hôpital Armand Trousseau, 75012 Paris, France; Unité de Formation et de Recherche (UFR) de Médecine Pierre et Marie Curie, Université Pierre et Marie Curie (UPMC) Université Paris VI (C.H., J.P.S., S.C.M.), Paris, France; Service d'Endocrinologie et Médecine de la Reproduction-CRMERC (B.D., S.C.M.), AP-HP, Groupe Hospitalier Universitaire de l'Est Parisien-Hôpital St-Antoine, 75012 Paris, France; Service d'Endocrinologie, Diabétologie et Maladies Métaboliques (V.K.), Centre Hospitalier Universitaire de Brest, La Cavale Blanche, 29200, Brest, France; Département de Génétique et Développement (C.D.), Institut Cochin, INSERM U1016, Université Paris-Descartes, Paris, France; Service de Gynécologie Endocrinienne et Médecine de la Reproduction (S.J.), Hôpital Jeanne-de-Flandre, 59037 Lille, France; Service d'Endocrinologie-Diabète-Nutrition (B.D.), Centre Hospitalier Universitaire (CHU) de Reims-Hôpital Robert-Debré, 51092 Reims, France; Unité de Gynécologie Endocrinienne (A.G.), Université Paris Descartes, Hôpital Port Royal, Paris, France; Service d'Endocrinologie (Y.R.), Centre Hospitalier Universitaire Côte de Nacre, 14000 Caen, France; and Service Endocrinologie et Médecine de la Reproduction-CRMERC (P.T.), AP-HP, Groupe Hospitalier Pitié-Salpêtrière, 75013, Paris, France.
Abstract
CONTEXT: Premature ovarian insufficiency (POI) may be secondary to chemotherapy, radiotherapy, or environmental factors. Genetic causes are identified in 20-25% of cases, but most POI cases remain idiopathic. OBJECTIVE: This study aimed to identify new genes involved in POI and to characterize the implication of CPEB1 gene in POI. DESIGN AND SETTING: This was a case report and cohort study replicate conducted in academic medical centers. PATIENTS AND METHODS: A deletion including CPEB1 gene was first identified in a patient with primary amenorrhea. Secondly, 191 sporadic POI cases and 68 familial POI cases were included. For each patient, karyotype was normal and FMR1 premutation was excluded. Search for CPEB1 deletions was performed by quantitative multiplex PCR of short fluorescent fragments or DNA microarray analysis. Gene sequencing of CPEB1 was performed for 95 patients. RESULTS: We identified three patients carrying a microdeletion in band 15q25.2. The proximal breakpoint, for the three patients, falls within a low-copy repeat region disrupting the CPEB1 gene, which represents a strong candidate gene for POI as it is known to be implicated in oocyte meiosis. No mutation was identified by sequencing CPEB1 gene. Therefore, heterozygous deletion of CPEB1 gene leading to haploinsufficiency could be responsible for POI in humans. CONCLUSION: Microdeletions of CPEB1 were identified in 1.3% of patients with POI, whereas no mutation was identified. This microdeletion is rare but recurrent as it is mediated by nonallelic homologous recombination due to the existence of low-copy repeats in the region. This result demonstrates the importance of DNA microarray analysis in etiological evaluation and counseling of patients with POI.
CONTEXT: Premature ovarian insufficiency (POI) may be secondary to chemotherapy, radiotherapy, or environmental factors. Genetic causes are identified in 20-25% of cases, but most POI cases remain idiopathic. OBJECTIVE: This study aimed to identify new genes involved in POI and to characterize the implication of CPEB1 gene in POI. DESIGN AND SETTING: This was a case report and cohort study replicate conducted in academic medical centers. PATIENTS AND METHODS: A deletion including CPEB1 gene was first identified in a patient with primary amenorrhea. Secondly, 191 sporadic POI cases and 68 familial POI cases were included. For each patient, karyotype was normal and FMR1 premutation was excluded. Search for CPEB1 deletions was performed by quantitative multiplex PCR of short fluorescent fragments or DNA microarray analysis. Gene sequencing of CPEB1 was performed for 95 patients. RESULTS: We identified three patients carrying a microdeletion in band 15q25.2. The proximal breakpoint, for the three patients, falls within a low-copy repeat region disrupting the CPEB1 gene, which represents a strong candidate gene for POI as it is known to be implicated in oocyte meiosis. No mutation was identified by sequencing CPEB1 gene. Therefore, heterozygous deletion of CPEB1 gene leading to haploinsufficiency could be responsible for POI in humans. CONCLUSION: Microdeletions of CPEB1 were identified in 1.3% of patients with POI, whereas no mutation was identified. This microdeletion is rare but recurrent as it is mediated by nonallelic homologous recombination due to the existence of low-copy repeats in the region. This result demonstrates the importance of DNA microarray analysis in etiological evaluation and counseling of patients with POI.
Authors: Asma Sassi; Julie Désir; Véronique Janssens; Martina Marangoni; Dorien Daneels; Alexander Gheldof; Maryse Bonduelle; Sonia Van Dooren; Sabine Costagliola; Anne Delbaere Journal: F S Rep Date: 2020-08-22
Authors: Fatma Eldefrawy; Hannah Shibo Xu; Elizabeth Pusch; Ashraf Karkoura; Mohamed Alsafy; Samir Elgendy; Susan M Williams; Kristen Navara; Tai L Guo Journal: Reprod Toxicol Date: 2021-06-18 Impact factor: 3.421
Authors: I Bestetti; C Castronovo; A Sironi; C Caslini; C Sala; R Rossetti; M Crippa; I Ferrari; A Pistocchi; D Toniolo; L Persani; A Marozzi; P Finelli Journal: Hum Reprod Date: 2019-03-01 Impact factor: 6.918